Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 18/20 | 0.48 |
| ▸ | JAK2 | O60674 | 17/20 | 0.48 |
| ▸ | JAK1 | P23458 | 9/20 | 0.48 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1991799 | 0.95 | FLT3 (0.54) | FLT3JAK3JAK2JAK1EIF2AK4 | |
| SCHEMBL1992529 | 0.91 | FLT3 (0.53) | FLT3JAK3JAK2JAK1 | |
| SCHEMBL12611701 | 0.91 | FLT3 (0.53) | FLT3JAK3JAK2JAK1 | |
| SCHEMBL1992612 | 0.91 | FLT3 (0.53) | FLT3JAK3JAK2JAK1 | |
| SCHEMBL12611068 | 0.90 | EIF2AK4 (0.45) | FLT3JAK3JAK2JAK1EIF2AK4 | |
| SCHEMBL2036201 | 0.88 | FLT3 (0.49) | FLT3JAK3JAK2JAK1 | |
| SCHEMBL2036200 | 0.88 | FLT3 (0.49) | FLT3JAK3JAK2JAK1 | |
| SCHEMBL2036588 | 0.88 | FLT3 (0.49) | FLT3JAK3JAK2JAK1 | |
| SCHEMBL2036590 | 0.88 | FLT3 (0.49) | FLT3JAK3JAK2JAK1 | |
| SCHEMBL2036730 | 0.88 | EIF2AK4 (0.46) | FLT3JAK3JAK2JAK1EIF2AK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | claimed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | claimed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-08-22 | — | — | US | disclosed |
| EP-2516436-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | Almirall S.A. (ES) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011076419-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338888-A1 | Imidazopyridine derivatives as JAK inhibitors | Almirall, S.A. (ES) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130216498-A1 | IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | FLT3 21/4885JAK3 3/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.